CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in RWE studies [16–18, 29, 30, 33, 34, 65, 66], which has led guidelines to support a favourable positioning for these agents early in the treatment pathway for patients with T2D in the setting of CV risk, HF and renal disease [37–41]. The gene discussed is SLC5A2; the disease is kidney disorder.